Ref: Syn/CS/SE/IP/2022-23/July/10

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

July 20, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2022. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to September 30, 2022.

The above-mentioned Investor Presentation will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,
Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

PRIYADARSHINI MAHAPATRA

Digitally signed by PRIYADARSHINI MAHAPATRA
DN: c=IN, o=Personal, pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9b276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef26229a00b5f723a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb1208536f4f186028 5e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA
Date: 2022.07.20 15:00:19 +05'30'

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Investor Presentation.

Syngene

Putting Science to Work

Investor Presentation

July 2022

Safe harbour

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Contents

1 Operating Highlights

Syngene

Q1 FY23 performance

Operating Highlights

- Strong underlying performance across all business divisions
- The contribution from the Development and Manufacturing Services divisions drove the growth momentum against a low base in the previous year.
- The Dedicated Centers and Discovery services divisions delivered continued growth
- Signed a 10year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind injectable monoclonal antibody to alleviate pain associated with osteoarthritis in dogs.
- Established kilo lab for polymer and speciality materials to reduce the development timelines for clients looking for customizable and flexible systems to expedite formulation and process development services

Q1 Financial Highlights

The first quarter results are against a strong quarter last year due to sales of remdesivir. Excluding the impact of remdesivir, the underlying revenue from operations growth in the quarter was around 30% year-on-year

Total Revenue **Rs. 6,600 Mn**	EBITDA **Rs. 1,883 Mn**
Profit After Tax **Rs. 739 Mn**	EBITDA **Margin at 29%** PAT **Margin at 11%**

*Proteolysis targeting chimeric

Syngene signs 10 year manufacturing deal with Zoetis worth up to $500Mn

- Marks an inflection point for Syngene's Development and Manufacturing Services Division
- Will position Syngene as a leading Contract Development and Manufacturing Organisation (CDMO) in animal health globally

About the deal

- Syngene will manufacture drug substance for Librela®, subject to regulatory approvals
- Product already launched in Europe, the UK and Switzerland and won 'Best new companion animal product' by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition
- Deal initially centered on Librela®, paves the way for development and manufacturing of other molecules in the coming years for Zoetis

Revenue:

- At full capacity utilization, Biologics business is expected to generate an asset turnover of about 1x
- Capacity utilization depends on market demand and is subject to regulatory approvals
- Around 10% of cumulative investment in Biologics

Margins

- EBITDA margins for Biologics depend on the complexity of process and raw material component. Margins are expected to be inline with overall Syngene margins as capacity utilization increases

Capex

- FY23 capex guidance of $100Mn factors ca.30% of capex for biologics

Above information is directional input for analyst modeling and is subject to safe harbour clause part of this document

Revised FY23 guidance: upgraded revenue growth from mid teens to high teens

Parameter	FY23 Guidance (April 2022)		Revised FY23 Guidance (July 2022)
Revenue from operations	Mid-teen growth	↑	High- teen growth
EBITDA Margin	EBITDA margin around 30%.	↔	EBITDA margins around 30%
PAT* Growth	PAT growth rate for the full year expected to be in single digit.	↔	PAT growth expected to be in single digit

*before exceptional items

2 Syngene – Putting Science to Work

Syngene

Partner in innovation: #Puttingsciencetowork

Who we are and what we do

Working with innovators from around the world to find solutions to their scientific challenges

Integrated solution provider across research, development manufacturing

Covering pharma, biotech, nutrition, animal health, consumer goods and specialty chemical

Clients across the globe

Innovative culture driven by the expertise of 7,500+ employees, state-of-the-art infra and market-leading technology



Well established in scientific research and development, emerging presence in commercial manufacturing of small and large molecules

Key facts and figures

420+
active clients

15
collaborations
with top 20 pharmaceutical companies

400+
Patents
held with clients

World class infrastructure
of 2 Mn sq. ft. qualified to meet international standards

Rs. 39,435 Mn
(US$526Mn*)
Gross Block of Investments ^

Rs. 26,570 Mn
(US$354Mn*)
FY22 Revenue

Rs. 4,211 Mn
(US$56Mn*)
FY22 PAT before exceptional item

87%
Talented team of scientists

*All figures are as on March 31, 2022, unless otherwise specified. *At Rs75/US$ ^Tangible and Intangible Assets*

International accreditations

- USFDA,OHSAS 18001,
- GLP, cGMP, AAALAC & CPCSEA Certified Facilities
- CAP accreditation, ISO/IEC 27001:2013 accreditation
- EMA and PMDA approved, AAALAC Accredited facility
- The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL).

Our experience spans multiple industry segments and partnerships with global leaders across the world

Large & Mid-Sized BioPharma

Bristol Myers Squibb
Albireo
gsk
SANOFI
Johnson & Johnson
MERCK
AMGEN
Baxter
abbvie

Emerging BioPharma (EBP)

Clinical-stage company creating novel medicines targeting

G protein-coupled receptors (GPCRs)

rodin THERAPEUTICS
sosei HEPTARES
PharmAust LIMITED
Genmab
ASCENEURON A Neurodegeneration Therapeutics Company

European clinical-stage biopharmaceutical focused on Oncology

Universities

Weill Cornell Medicine
Indiana University
UK Research and Innovation
University of Glasgow
VCU VIRGINIA COMMONWEALTH UNIVERSITY
KING ABDULAZIZ UNIVERSITY

Animal Health

zoetis
MERCK
BAYER

AgroChem

FMC

Leading China based crop protection company

Large Japanese chemical company

Large MNC focussed on Agriculture & Nutrition segments

Consumer products

Global food and beverage company

Unilever

Our journey so far



Foundation
- Operations started
- Expansion of R&D Lab
- Granted 100% EOU status by the Government of India

Expansion
- Expanded service offerings to include chemical development, safety assessment, biologics development
- Collaboration with BMS to set up BBRC, Syngene's first dedicated R&D Center

Globalization and strategic collaboration
- Expanded into formulations development
- Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules
- Collaboration with Baxter to set up a dedicated R&D center
- Extension of collaboration with BMS; Merger of Clinigene
- Crossed annual turnover of Rs. 5 Billion

IPO and further collaborations
- IPO and listing
- Collaboration with Amgen to set up a dedicated R&D center

Continued investments and growth
- Expanded collaboration with BMS; Baxter Amgen and Zoetis
- Expansion of IDD platform
- Laboratory capacity expansion in Bangalore, Hyderabad
- Expansion in Mangalore for commercial API mfg.
- Capacity and capability addition in Biologics manufacturing

Our span across the value chain, making us *one-stop solution provider* enabling us to capture the opportunity

Research business

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule, Peptide, Oligos, ADC, PROTACs

SynVent Platform for Integrated Drug Discovery

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive, dedicated operations for an individual client

Multi-disciplinary scientists

Access to entire Syngene ecosystem for research and development operations

Development and Manufacturing business

Development Services

Pre-clinical to clinical trials

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the art API manufacturing and biologics manufacturing facilities

Our collaboration models

1

Dedicated R&D Labs

- Dedicated scientific and support teams work exclusively on the client's project
- Clients are provided with customized and ringfenced infrastructure
- Long-term strategic alliances that last usually five years or more

2

FTE

- Pre-defined numbers of scientific personnel from pre-determined disciplines work full-time on client projects
- Deliverables and team composition evolve as the project advances
- Agreements are typically renewed annually

3

FFS

- Client collaboration to deliver agreed services within a defined scope.
- Flexible, on demand personnel and research infrastructure deployed to achieve the project objectives
- Engagements may be short or long-term

4

Productivity based model

- Offer the services directly linked to productivity generated by our team

5

Risk-reward

- Across a portfolio of stage gate-driven research projects
- Client benefits from reduced upfront payments in exchange for significant success-based milestone payments against pre agreed criteria

6

Delivery based contract for CDMO business

- Per Kg Per Batch model with built in milestones progressing towards achievement of outcome and delivery of drug substance, drug product

… and are open to any single or combination of above

Backed by world class state of the art infrastructure

HQ Campus
90 acres in Bangalore where most of Syngene's capabilities are housed today

Biologics Expansion
HQ Campus Biologics Manufacturing plant scale:
Mammalian- ~100-2000L
Microbial - ~200-500L

R&D Expansion Genome Valley, Hyderabad, India commenced operation in Aug 2019

API Manufacturing Expansion
Commercial Manufacturing to support product launch in Mangalore, India - Commenced operation in March 2020; Capacity: 70KL; Reactor size: 2-12KL

Agile and experienced workforce; Building capabilities and careers to sustain growth

~6000
strong total headcount

87% scientists delivering quality output and creating competitive edge



Environment that engages our employees and enables them to grow

Nurturing fresh talent and science

- Syngene Training Academy (STA) offers recruits a six-month extended induction to help them understand and align with Company's goals, vision and core values as well as learning skills of an industrial scientist
- Science Certification Program aims to enhance capabilities of scientific staff and provide opportunities for continuous learning. The program comprises multiple modules delivered by recognized industry leaders and academics

Upskilling managers

- Emerging Leaders Development Program identifies emerging management talent and support those individuals to transition from managerial to leadership roles
- Providing training in people management, communications and performance management to equip managers realize their potential and make positive contributions to the organizational goals.

Promoting workplace diversity

- 27% female employees vs 16% in FY16
- 34% of employees onboarded were female. Company had 22% females in management positions, as against 14% in FY21.

Operational robustness driving strategy execution

Established model of continuous improvement driven by certified operational leaders

Six Sigma Black Belt certified staff in each service line and support functions

Green belt certified staff across operations

All employees white belt certified

Expansion of footprint and organization wide capabilities to support growth

Lab space expansion in Hyderabad, capacity expansion in biologics

Anytime audit ready organization

Process automation and digitization

7 successful USFDA audits in the last 4 years

Digital as a differentiator

AI Platform

IOT for maintenance and infrastructure reliability

Data Management, IT infrastructure and security systems that strengthen our proposition as a strategic partner to clients

Strong and distributed commercial organization

Leaders based out of US, Europe, UK and Asia

Closer to client locations

Strategic Sourcing that makes a difference

Strong resilient supply chain capabilities successfully navigating global supply chain disruption

Supply sources distributed across the world to ensure business continuity

3 Strategic Advantages

Syngene

Syngene's Strength

A Global CRO/CDMO
- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and Large Molecules, ADCs, Oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)

IP Position
- IP can be fully assigned to clients
- Strong track record of Data Integrity and Security
- Over 400+ patent assignments by clients recognizing Syngene

Quality Focus
- Quality driven organization
- Excellent track record of compliance with global regulators
- US FDA, EMA and PMDA approved, GLP Certified, AAALAC Accredited facility
- 15+ regulatory and ~250 client audits in the last 3 years



Scientific Ecosystem
- 2 Mn sq. ft.world-class R&D and Manufacturing infrastructure
- Sites in Bangalore, Mangalore, and Hyderabad
- ~5300 qualified scientists including ~500 PhDs
- Highly effective supply chain practices
- Large molecule capacity of 10,000 L and small molecule capacity of 70,000 L

Marquee
+ ~ 420 active clients
- Partnering with large / mid-size / emerging BioPharma (EBP) and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors

Track Record
- Collaborations and partnerships to deliver numerous clinical candidates
- Delivery history for integrated CMC programs towards FIH and beyond

Strong track record of growth and profitability

Total Revenue (Rs. Mn)

FY18 to FY22 - CAGR 16%



EBITDA (Rs. Mn)

FY18 to FY22 - CAGR 13%



Profit Before Tax * (Rs. Mn)

FY18 to FY22 - CAGR 8%



Gross Block^ (Rs Mn)



EBITDA margins

Sustained above 32%



Profit After Tax * (Rs. Mn)

FY18 to FY22 - CAGR 8%



*Before exceptional items

^Tangible and Intangible Assets

Multiple levers for growth going ahead

Expand/Extend Existing Clients
- High service integration
- Dedicated centers model

Engage New Clients
- Tailored service offerings and dedicated personnel



Capacity Expansion
- Consistent investment
- FTE services, manufacturing, formulation, biologics, stability

Offtake in commercial manufacturing in both biologics and small molecule API

Integrated Drug Discovery
- Go to model, with an integrated scientific solution provider, delivering end to end client's requirements

Capability Additions
- New capabilities across multiple domains incl. the allied sectors
- Stability, analytical and bio-analytical services, viral testing, Oligonucleotide bioinformatics
- New platforms: ADC,CAR-T,PROTACs

Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules)





** Human Pharmacology Unit*

Discovery Services






	Target Identification and Validation	Hit Identification	Hit to Lead	Lead Optimization	IND Enabling	IND / Ph1 DE
Biology Translation	**Target ID** 1. Pathway analysis 2. Omics 3. Knock-in / knock-out **Hypotheses:** 1. Therapeutic 2. Mechanistic 3. Target Engagement	***In vitro* assays:** 1. Biochemical 2. Orthogonal 3. HTS Formats	***In vitro* assays:** 1. Cellular Mechanistic 2. Cellular Functional 3. Relevant Off-Target(s) ***In vitro* ADME assays:** 1. Protein Binding 2. Metabolism 3. CYP Inhib/Induct **Research Operating Plan:** 1. Assay Priority 2. Key Studies 3. Critical Path	***In vivo* assays/studies:** 1. PK (R/NR) 2. PD, PK/PD 3. Efficacy **Hypothesis:** 1. Patient Selection	**Later Translational:** 1. PK/PD/Efficacy 2. Refinement of patient selection hypothesis 3. Biomarkers **Human Dose Projection** 1. h-PK Projection 2. PK/PD/Efficacy data 3. Safety/Tox data	**Ph1-HV or Patient (as appropriate):** 1. Exposure 2. PD
Chemistry Development Formulation Clinical Development		**HTS/DEL/Fragments/Virtual Screening** 1. Library Design/Synthesis/ Maintenance 2. Hit validation, Resynthesis 3. Series Qualification, Prioritization	**Optimization:** 1. Biochem/Cell Potency 2. Selectivity 3. Phys/Chem Properties 4. In Vitro/Vivo Tool Cmpds	**Optimization:** 1. Tgt Optimal h-Profile 2. Candidate Selection 3. Backup Strategy	**Drug Substance (DS, aka API)** 1. Route Scouting (define specs) 2. Scale Up 3. Manufacture/Stability	**Drug Product (DP)** 1. Pre-Formulation Studies 2. Ph1 Suitable Formulation 3. Prototype/Stability 4. Manufacture/Stability 5. IND, BA/BE, DDI and Phase 1 clinical trials 6. GCP Bioanalysis
Safety Assessment			***In vitro* Safety:** 1. hERG 2. Ion Channels	**Tox-Suitable Formulation (maximize exposure)**	DRF Tox (R/NR) Bioanalysis GLP Tox (R/NR) GLP Bioanalysis	MTD or RP2D (as appropriate)

Informatics → **Iterative Data Analysis and Interpretation, Models, Hypothesis Generation**

Development Services and Manufacturing Services





	Developability Assessment	Development phase	Clinical Phase			Registration/process validation	Commercial batches
			Phase I	Phase II	Phase III		
Safety Assessment	Early PK, MTD/DRF studies, Exploratory Tox	• IND enabling GLP Tox studies: Ames, Chromosomal aberration, Micronucleus tests, Pivotal repeat dose (Rodent and Non- rodent) • Safety Pharmacology: CNS, Respiratory, CV Telemetry, hERG		• NDA enabling studies: Sub- chronic and Repro-tox studies • Local Tolerance study	Chronic and Carcinogenicity study		
Chemical Dev and Manuf.	• Route scouting • Process safety evaluation • Scalability	• Fit to purpose Process dev • Material supply • Impurity identification • Enable and scale • Tox material delivery	• Process dev , robustness and safety study • Unit operation studies • Impurity synthesis & characterization • DS clinical batch supply			• Process DOE, QBD and scale up studies • Process Risk assessment • FMEA analysis • Registration and process validation batches manuf.	Commercial batches manuf. and packaging
Formulation Dev and Manuf.	• Pre-formulation • Salt polymorph screening • Excipient compatibility	• Solid Oral & Injectable dosage forms • Enabling formulation technologies	Clinical Supplies for all phases • FIH formulation for Phase 1/2A • Final dosage form for Phase 2B/3 and onwards				
Analytical Services	Methods for Pre-formulation and Bio-analytical	• Methods for Intermediate, Final DS, DP • Forced degradation studies • Solid state characterisation	• Phase appropriate method validation for DS & DP (microbial methods) • Specifications for DS & DP • In process and Finished product analysis • Final batch release with COA • Reference standard , Impurities, Isolation and characterisation			Robustness of Analytical methods and full validation as per ICH	Analysis of commercial batches
Stability Services	Selection of suitable container closure system & packaging	• Development stability studies	• ICH stability for all phases • Shelf life Estimation • Re-test extension			Stability study of registration/ process validation batch	Stability study of commercial batches
Clinical Development			• Human Pharmacology Unit (Phase I/BE studies) • Clinical Trial Services – full solution provider for conducting trials in India • Central Lab Services including regulated bioanalytical lab • Clinical data management, biostatistics and medical writing				

Regulatory Support

Biologics Development and Manufacturing services





	Developability Assessment	Development phase	Clinical Phase			Registration/process validation	Commercial batches
			Phase I	Phase II	Phase III		
Process & analytical development	• Cell line development / selection • Process screening • Process characterization	• Clone to GMP • Upstream process Optimization • Viral clearance studies	• Process DOE, robustness and safety study • Unit operation studies • Impurity synthesis & characterization • DS clinical batch supply (non-GMP clinical & GMP) • CMC & regulatory support • Method development & testing			• Process risk assessment • FMEA analysis • Tech transfer package	• Commercial batches • manufacturing and packaging • technical support
Scale-up & QC/QA	• Methods for pre-formulation and bio-analytical	• Methods for intermediate, final DS, DP • Critical to quality parameter identification • Forced degradation studies	• Clinical phase process development & supply • Specifications for DS & DP • In process and finished product analysis • Viral clearance studies • Packaging and ICH storage stability and shelf-life estimation			• 3-Lot testing & equipment validation • Cleaning validation studies • Pre-audit preparation	• QC/QA analysis & release of commercial product w/ COA • Stability analysis • Root cause Investigation & CAPA management
Commercial production & supply chain	• Early screening of asset capability and capacity	• Capacity utilization planning	• Late phase clinical supply using manufacturing scale equipment • Supplier identification • Waste management plan • CAPEX requirement identification			• Supplier qualification • Pre-audit preparation • Protocol documentation • Master batch record development • Operation training	• Sales and operations planning • Delivery / logistics • Customer & regulatory audits • Process improvement & Regulatory filing updates

Regulatory Support

Led by a globally experienced management team

Jonathan Hunt
Managing Director and Chief Executive officer

Experience

AstraZeneca

Sibaji Biswas
Chief Financial Officer

Vodafone,
Hutchison Telecomm

Dr. Mahesh Bhalgat
Chief Operating Officer

Sanofi, Amgen,
Monsanto

Ashu Tandon
Chief Commercial Officer

IQVIA
Accenture

Sanjeev Sukumaran
Chief Human Resources Officer

Thomson Reuters

Alok Mehrotra
Chief Quality Officer

Experience

Reckitt Benckiser,
PepsiCo, Godrej, DRL

Caroline Hempstead
Head of Corporate Affairs

AstraZeneca

Dr. Kenneth Barr
SVP Discovery Services

FORMA
Merck

Alex Del Priore
SVP Manufacturing

Johnson Matthey

Advised by Our Board of Directors

Kiran Mazumdar Shaw
Non-Executive Chairperson

Experience

Chairperson of Biocon Limited, ~45 years of experience in the field of biotechnology

Jonathan Hunt
Managing Director and Chief Executive officer

~30 years of experience in the global biopharmaceuticals industry

Dr. Carl Dcicco
Independent Director

Chief Scientific Officer in Foghorn Therapeutics

Professor Catherine Rosenberg
Non-Executive Director

Professor in electrical and computer engineering at the University of Waterloo, Canada

Vinita Bali
Independent Director

Chief Executive Officer & MD of Britannia Industries from 2005 to 2014

Paul Blackburn
Independent Director

Experience

40 years+ experience in the field of finance

Sharmila Abhay Karve
Independent Director

Retired as audit partner from Price Waterhouse

Dr Vijay Kuchroo
Independent Director

Founded five biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals

Kush Parmar
Independent Director

Managing Partner at 5AM Ventures, a life sciences venture capital firm

Committed to sustainability

Safety is at the heart of everything we do

- Accredited with ISO 45001:2018 for its Occupational Health and Safety (OH&S) measures
- Risk assessments are the integral part of our operation - a proactive approach in incident prevention
- 21,761 man hrs of regular safety training under Kavach, our flagship safety program considerable improvement across several safety metrics
- 13.7 million manhours without Lost Time Incident (LTI) on rolling 12-month basis for FY22

Increased incident reporting	**Reduction of incidents**
Improved risk control measures	**Improved general safety perception**

Committed to environmental protection

- Accredited with ISO 14001:2015 for its effective Environment Management System (EMS)
- **34,000 KL** of water conserved through effective rainwater harvesting as well as recycling of used water; up 61% from FY21
- **92%** of the total waste generated are recycled in an environment-friendly manner for FY22
- **3-R's** Operations constantly monitored to identify opportunities to reduce, reuse, and recycle waste
- **67,000 tons** of carbon dioxide emissions reduced in FY22,up 26% from FY21
- **74 Mn KWH** of electricity usage through Green energy sources; up 18% from FY21
- **85%** of Energy consumption is through green energy sources in FY22

Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development

All figures are as on March 31, 2022, unless otherwise specified

We have consistently received industry recognition for our scientific capability and best practices

- **Bio-Excellence Award 2018:** At Bengaluru Tech Summit, Bengaluru
- **Best Bioprocessing Excellence Award 2018** - At 5th Biologics Manufacturing Asia, Singapore
- **Healthcare Company of the Year 2018:** At the 7th Annual VC Circle Awards 2018, Mumbai
- **HR Excellence Award 2018 'For Best Talent Management Strategy':** World HRD Congress, Mumbai

- **CMO Leadership Award Winner 2020 -** under Categories: Capabilities, Compatibility, Expertise and Service
- Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia—Viral Clearance and Safety Testing'
- **Great Place to Work Certified™ Company**
- (ASSOCHAM) CSR & NGO Awards 2020 for our contribution to COVID-19 relief work in Karnataka.

- **CMO Leadership Awards 2022** Received 6 awards for all categories, including Capabilities, Compatibility, Expertise, Quality, Reliability and Service
- **CMO Leadership Award Champion 2022** Additional Recognition received in CMO Leadership Awards 2022 for top performance in all **categories**
- **'Most Preferred Workplaces of 2022' by Team Marksmen Daily in association with India Today** Recognized for its holistic reorientation of the business landscape in the context of the pandemic, and for creating a collaborative and empowering culture for its employees.

2018 | **2019** | **2020** | **2021** | **2022**

- Ranked as one of the **25 fastest growing companies in India** by Outlook Business
- **CMO Leadership Awards 2019** - Presented by Life Science Leader Magazine
- **FICCI CSR Award for Environmental Sustainability** -At the 17th Edition of the awards in New Delhi
- **Safe Workplace Champion Award** - At the 8th Manufacturing Supply Chain Summit and Awards
- **Best Leadership Development Program for Middle Management Award** - At the 6th Global Training and Development Leadership Awards
- **India Pharma Award 2019** - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo.
- **Utthama Suraksha Puraskar 2019 - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards**

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma:** for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence: Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Most Innovative New Learning Programme** at the L&D Vision & Innovation Award organized by Transformance Forums
- **Mahatma Award 2021** Under Health & Wellbeing Category
- **Best Corporate Foundation Award** at the World CSR Congress

Proactively managing risks through robust risk management framework

Syngene has a risk management framework to identify, monitor, report and manage risk across the business.
Every risk owner monitors and manages risks relevant to their area of responsibility.

Risk Owner

- Identify and mitigate risk in respective business areas

Executive Committee (EC)

- Sign off on Enterprise Risk Framework – Annually
- Review and approve the key updates to enterprise risks and deep dive into few risk areas every quarter

Risk Committee

- Sign off on Enterprise Risk Framework – Annually
- Ensure that appropriate measures are in place to mitigate the risks
- Review key updates to enterprise risks and deep dive into few risk areas every quarter

Board of Directors(BOD)

- Provide strategic direction on mitigation of risks
- Ensure principal risks are properly managed

Risk identification → **Risk assessment** → **Risk analysis and rating** → **Risk mitigation** → **Monitoring and reporting**

Refer Annual report for complete risk profile and risk mitigation strategy

4 Financials

Syngene

Q1 financial highlights

Particulars	Q1 FY23	Q1 FY22	YoY Change	Q4 FY22	QoQ change
Revenue from Operations	**6,445**	**5,945**	8%	**7,581**	(15%)
Other Income	155	123	26%	147	6%
Total Revenue	**6,600**	**6,068**	9%	**7,728**	(15%)
Material and Power Costs	1,791	2,082	(14%)	2,325	(23%)
Employee Costs	1,861	1,711	9%	1,736	7%
Foreign exchange (gain)/loss, net	34	(154)	(122%)	(91)	(137%)
Other Expenses	1,031	656	57%	1,108	(7%)
EBITDA	**1,883**	**1,773**	6%	**2,650**	(29%)
EBITDA Margin	***28.5%***	***29.2%***		***34.3%***	
Depreciation and finance cost	955	826	16%	859	11%
PBT	**928**	**947**	(2%)	**1,791**	(48%)
Tax on above	189	174	9%	313	(40%)
PAT	**739**	**773**	(4%)	**1,478**	(50%)
PAT Margin	***11%***	***13%***		***19%***	

All figures in Rs. Mn unless otherwise specified

FY22 financial highlights

Particulars	FY22	FY21	YoY Change
Revenue from operations (excl export incentives)	**26,042**	**21,843**	**19%**
Other Income	528	646	(18%)
Total Revenue	**26,570**	**22,489**	18%
Material and power costs	8,138	5,839	39%
Employee costs	7,181	6,602	9%
Foreign exchange (gain)/loss, net	(548)	(171)	220%
Other Expenses	3,310	2,855	16%
EBITDA	**8,489**	**7,364**	15%
EBITDA Margin (%)	**32%**	**33%**	
Depreciation, Interest and tax	4,278	3,543	21%
Profit After Tax before exceptional item	**4,211**	**3,821**	10%
PAT Margin (%)	***16%***	***17%***	
Exceptional Items, net of taxes [3]	(253)	228	
Profit After Tax after exceptional item	**3,958**	**4,049**	(2%)

Balance Sheet Highlights

As on 31st March 2022

Shareholders' funds	32,976
Net Fixed assets	27,392
Other net assets [1]	(1,741)
Net cash/(debt) [2]	7,325
Total Use of Funds	32,976

(1) Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less (Trade payables + Others current liabilities) at the end of the year
(2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year
(3) Exceptional item in FY22 is in relation to reversal of services export incentive related to FY20 in line with Government notification. In FY21 relates to receipt from insurance claim

All figures in Rs. Mn unless otherwise specified

5 Shareholding and Share Information

Syngene

Biocon Group and Syngene

Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company

Syngene, a subsidiary of Biocon Limited, was established in 1993 as India's first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecule discovery, development and manufacturing services

Biocon Biologics, another subsidiary of Biocon Limited, consolidates the development, manufacturing and commercialization operations of Biocon's biosimilars business

Syngene

Integrated services:

- Discovery
- Development
- Manufacturing small/large molecules



- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs

Biocon

Biocon Biologics

Shareholding and Share Information

Syngene's Shareholding Pattern*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Mn)	2,22,342
% free-float	29%
Free-float market cap (Rs. Mn)	64,326
Share Outstanding (Mn)	401
3M ADTV ^ (Shares)	4,14,768
3M ADTV ^ (Rs. Mn)	248

*As on 30th June 2022

^ NSE Average Daily Traded Volume / Value

For more details

Visit our website www.syngeneintl.com

https://twitter.com/SyngeneIntl

https://www.linkedin.com/company/syngene-international-limited

https://www.facebook.com/syngeneintl/

https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ

IR Contact:
Krishnan G
+ 91 806 891 9807
investor@syngeneintl.com

Media Contact:
Shotorupa Ghosh
+91 8450977080
Shotorupa.ghosh@syngeneintl.com

Syngene

Putting Science to Work

Thank you